Stockreport

LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF Only PARP Inhibitor to Improve Overall Survival vs. New Hormonal Agent Treatments for Advanced Prostate Cancer, A Key Secondary Endpoint KENILWORTH, N.J.--(BUSINESS W [Read more]